Blood Res 2023; 58(4):
Published online December 31, 2023
https://doi.org/10.5045/br.2023.2023178
© The Korean Society of Hematology
Correspondence to : Verónica Roldán Galiacho, M.D., Department of Hematology, Cruces University Hospital, Barakaldo, Bizkaia 48903, Spain, E-mail: veronica.roldangaliacho@osakidetza.eus
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
A 53-year-old man presented with weight loss and lymphadenopathies. Following were the blood-work findings: hemoglobin 109 g/L, platelets 63×109/L, leukocytes 18.9×109/L, and lactate dehydrogenase 1,784 U/L. Peripheral blood film showed 22% of medium-sized atypical lymphocytes with flower-shaped nuclei, resembling adult T-cell lymphoma lymphocytes (A–E). Flow cytometry displayed a 25% lambda clonal lymphocytes CD19+, CD20+, CD22+, CD5+, CD10-, CD23-, CD200+, CD38+, CD25+, CD11c-, CD123-, and TdT-. Positron emission tomography/computed tomography revealed multiple hypermetabolic lymph nodes and captation in bone and spleen. Lymph node biopsy revealed a massive lymphocytic infiltrate positive for CD20, CD5, MUM1, FOXP1, BCL2, and MYC; negative for CD10, CyclinD1, SOX11, CD30, and EBER; with ki67 90%. Fluorence in situ hybridization targeting BCL6, BLC2 and MYC were negative. Bone marrow was infiltrated by lymphoma and the cytogenetic analysis showed a complex karyotype and TP53 deletion. Diffuse large B-cell lymphoma (DLBCL) non-germinal-center CD5+ double expresser was diagnosed.
CD5+ DLBCL is an uncommon subtype (5–10%) associated with older age-groups, extra-nodal involvement, inferior response to rituximab containing regimens, and poor prognosis.
Leukemic presentation of DLBCL is rare. Peripheral blood smear may be useful to screen it, being sometimes difficult to distinguish from other hemopathies. Although cytometry is a rapid testing tool in this cases, the final diagnosis should be made by biopsy including cytogenetic analysis.
Blood Res 2023; 58(4): 165-165
Published online December 31, 2023 https://doi.org/10.5045/br.2023.2023178
Copyright © The Korean Society of Hematology.
Verónica Roldán Galiacho1, Paula Zoco Gallardo1, Laura Zaldumbide Dueñas2, Bernabé Dávila De Las Fuentes3, Juan Carlos García-Ruiz1,4
Departments of 1Hematology, 2Pathology, 3Immunology, 4BioCruces Health Research Institute, Cruces University Hospital, Barakaldo, Bizkaia, Spain
Correspondence to:Verónica Roldán Galiacho, M.D., Department of Hematology, Cruces University Hospital, Barakaldo, Bizkaia 48903, Spain, E-mail: veronica.roldangaliacho@osakidetza.eus
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
A 53-year-old man presented with weight loss and lymphadenopathies. Following were the blood-work findings: hemoglobin 109 g/L, platelets 63×109/L, leukocytes 18.9×109/L, and lactate dehydrogenase 1,784 U/L. Peripheral blood film showed 22% of medium-sized atypical lymphocytes with flower-shaped nuclei, resembling adult T-cell lymphoma lymphocytes (A–E). Flow cytometry displayed a 25% lambda clonal lymphocytes CD19+, CD20+, CD22+, CD5+, CD10-, CD23-, CD200+, CD38+, CD25+, CD11c-, CD123-, and TdT-. Positron emission tomography/computed tomography revealed multiple hypermetabolic lymph nodes and captation in bone and spleen. Lymph node biopsy revealed a massive lymphocytic infiltrate positive for CD20, CD5, MUM1, FOXP1, BCL2, and MYC; negative for CD10, CyclinD1, SOX11, CD30, and EBER; with ki67 90%. Fluorence in situ hybridization targeting BCL6, BLC2 and MYC were negative. Bone marrow was infiltrated by lymphoma and the cytogenetic analysis showed a complex karyotype and TP53 deletion. Diffuse large B-cell lymphoma (DLBCL) non-germinal-center CD5+ double expresser was diagnosed.
CD5+ DLBCL is an uncommon subtype (5–10%) associated with older age-groups, extra-nodal involvement, inferior response to rituximab containing regimens, and poor prognosis.
Leukemic presentation of DLBCL is rare. Peripheral blood smear may be useful to screen it, being sometimes difficult to distinguish from other hemopathies. Although cytometry is a rapid testing tool in this cases, the final diagnosis should be made by biopsy including cytogenetic analysis.